On Tuesday, June 9, 2020, Pioneer Institute and the Boomer Esiason Foundation hosted an educational webinar, Protecting Cystic Fibrosis Patients from Discrimination by ICER Through COVID-19 & Beyond, on the importance of protecting patients with cystic fibrosis and any other complex condition from the harms of ICER. The webinar provided an important opportunity to learn more about the impact of ICER on the CF community.

As the devastating effects of coronavirus have impacted American communities, it has become more critical than ever to protect the health and well-being of our nation’s most vulnerable citizens. Despite this, in the middle of the COVID-19 pandemic, the Institute for Clinical and Economic Review (ICER) released an evaluation that would limit treatment options for cystic fibrosis (CF) patients. We encourage you to read more from one of our expert panelists on the webinar about what this evaluation means for patients with cystic fibrosis.

Morning Consult: A Flawed Economic Model Should Not Be Used to Deny Access to a Miracle Medication (May 5, 2020)

ICER poses ethical, methodological, and condition-specific concerns when it comes to treatment areas and specific diseases. Patients, their physicians and caregivers, and a variety of other societal factors should determine the value of these therapies. Learn more about the threat posed by ICER and how to take action here.